-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2023-505267-36-00
5
2024-03-15
Glioblastoma
-
2023-506714-43-00
4
2024-03-15
ALK positive Non-Small Cell Lung Cancer
-
2023-505251-43-00
5
2024-02-28
Primary Biliary Cholangitis
-
2023-506662-31-00
4
2024-02-28
Gastric or gastroesophageal cancer
-
2023-504150-35-00
6
2024-02-21
Endometrial cancer
-
2023-503708-10-00
5
2024-02-20
Locally advanced or metastatic breast cancer
-
2023-503521-19-00
5
2024-02-09
Duchenne muscular dystrophy (DMD)
-
2022-502741-10-00
7
2024-01-26
Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearrangement or Nucl
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2023-506971-89-00
5
2024-01-25
Coronary Artery Disease
-
2024-518888-35-00
4
2024-01-24
amyotrophic lateral sclerosis patients
-
2023-503462-23-00
5
2023-12-28
Lung transplant rejection
-
2023-506102-39-00
4
2023-12-18
metastatic gastric cancer
-
2022-502775-29-01
5
2023-12-14
Early stage Follicular Lymphoma
-
2023-509793-38-00
4
2023-11-24
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like mo
-
2022-501869-41-00
9
2023-11-14
Acute Lymphoblastic Leukemia, in Relapse
Lymphoblastic Lymphoma (Precu
-
2022-502273-42-00
5
2023-11-08
Glaucoma
-
2023-503295-25-00
10
2023-10-31
Resectable biliary tract cancers
-
2022-502021-18-00
6
2023-10-12
Rheumatoid Arthritis
-
2024-513562-19-00
5
2023-08-30
End-Stage Kidney Disease
-
2022-501822-39-00
9
2023-07-31
Glioblastoma
-
2023-510431-11-00
4
2023-07-21
Chronic Lymphocytic Leukemia
-
2022-502415-11-00
5
2023-06-16
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)